russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2014-11-51-56russjcardiol-108Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESВЗАИМОСВЯЗЬ ЛИПОПРОТЕИН-АССОЦИИРОВАННОЙ ФОСФОЛИПАЗЫ А2 С КОРОНАРНЫМ И КАРОТИДНЫМ АТЕРОСКЛЕРОЗОМ В КИРГИЗСКОЙ ЭТНИЧЕСКОЙ ГРУППЕRELATIONSHIP OF LIPOPROTEINE-ASSOCIATED PHOSPHOLIPASE A2 WITH CORONARY AND CAROTID ATHEROSCLEROSIS IN KIRGIZ ETHNIC GROUPПолупановA. Г.PolupanovA. G.

Доктор медицинских наук, ведущий научный сотрудник отделения артериальных гипертензий

polupanov_72@mail.ruЛомтеваЮ. Н.LomtevaYu. N.

Аспирант  отделения  артериальных гипертензий

polupanov_72@mail.ruРомановаТ. А.RomanovaT. A.

Доктор медицинских наук, заведующая отделением артериальных гипертензий

polupanov_72@mail.ruДжумагуловаА. С.DzhumagulovaA. S.

Доктор медицинских наук, профессор, директор Национального центра

polupanov_72@mail.ruНациональный центр кардиологии и терапии имени академика М. Миррахимова при МЗ КР, БишкекКыргызстанNational Centre for Cardiology and Therapy n.a. Academician M. Mirrakhimov of the Ministry of Health of Kirgiz Republic, BishkekKyrgyzstan2014281120140115156Copyright © Полупанов A.Г., Ломтева Ю.Н., Романова Т.А., Джумагулова А.С., 20142014Полупанов A.Г., Ломтева Ю.Н., Романова Т.А., Джумагулова А.С.Polupanov A.G., Lomteva Y.N., Romanova T.A., Dzhumagulova A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/108Цель

Цель. Изучение ассоциации уровня (массы) липопротеин-ассоциированной фосфолипазы А2 с наличием коронарного и каротидного атеросклероза у больных эссенциальной гипертензией в киргизской этнической группе.Материал и методы. Обследовано 52 больных эссенциальной гипертензией (ЭГ); средний возраст — 54,9±6,7 лет, в том числе 26 мужчин и 26 женщин. ИБС, верифицированную при проведении нагрузочных проб или коронароангиографии, имели 19 пациентов, атеросклеротическое поражение сонных артерий — 28 больных. Всем больным были проведены следующие обследования: измерение роста, веса и объема талии, измерение АД и ЧСС, а также определение ряда биохимических показателей: уровня фибриногена, сахара, креатинина крови и липидного спектра (уровни общего холестерина, ЛПНП, ЛПВП и триглицеридов). Определение массы ЛП-ФЛА2 проводилось с помощью “PLAC” теста фирмы “DiaDexus” (США) методом иммунотурбодиметрии в формате “ELISA”. Дуплексное сканирование сонных артерий проводили на аппарате Sequoia — 512, фирмы “Acuson” (США).Результаты. Выявлялась прямая корреляционная зависимость уровня ЛПФЛА2 с возрастом (r=0,27; p<0,05), концентрацией ХС-ЛПВП (r=0,30; p<0,05) и ХС-ЛПНП (r=0,28; p<0,05) и отрицательная ассоциация с уровнем триглицеридов (r=-0,28; p<0,05). Существенных гендерных различий по уровню ЛПФЛА2 не выявлено (p>0,05). Пациенты с ИБС имели более высокий уровень ОХС (5,64±0,97 ммоль/л против 5,23±1,33 ммоль/л, р=0,057), ХС-ЛПНП (3,63±0,89 ммоль/л против 3,16±0,98 ммоль/л, p<0,01), а также массы ЛПФЛА2 (296±70 нг/мл против 237±76 нг/мл, p<0,005) по сравнению с больными ЭГ без ИБС. При проведении мультифакторного регрессионного анализа оказалось, что только концентрация ЛП-ФЛА2 независимо ассоциировалась с наличием ИБС среди коренного населения республики (β=0,66; p<0,001). Нами не было обнаружено ассоциации уровня ЛП-ФЛА2 с наличием и выраженностью каротидного атеросклероза и толщиной комплекса интима-медия сонных артерий (p>0,05).

Заключение

Заключение. В киргизской этнической группе выявляется ассоциация уровня ЛП-ФЛА2 с наличием ИБС, но не с наличием каротидного атеросклероза.

Aim. To study the association of the level (mass) of lipoproteine-associated phospholipase A2 with coronary and carotid atherosclerosis in the patients with essential arterial hypertension in Kirgiz ethnic group.Material and methods. Totally 52 patients studied with arterial hypertension (AH); mean age — 54,9±6,7, of those 26 men and 26 women. CHD, confirmed by exercise tests or coronary arteriography, had 19 patients, atherosclerosis of carotid arteries – 28. All patients underwent height measurement, weight and waist circumference, BP and HR measurement, also measurement of some biochemical values: fibrinogene level, sugar, creatinine of the blood and lipid profile (levels of total cholesterol, LDL, HDL and triglycerides). Measurement of LP-PLA2 was done using “PLAC” test by “DiaDexus” (USA) with immuneturbodimetry method “ELISA”. Duplex scanning of carotid arteries was done with Sequoia-512 by “Accuson” (USA).Results. There was direct correlation of LP-PLA2 correlation with the age (r=0,27; p<0,05), HDL concentration (r=0,30; p<0,05) and LDL (r=0,28; p<0,05) and negative association with triglycerides (r=-0,28; p<0,05). Significant differences by gender in LP-PLA2 were not found (p>0,05). Patients with CHD had higher level oftotal cholesterol (5,64±0,97 mmol/l vs. 5,23±1,33 mmol/l, р=0,057), LDL (3,63±0,89 mmol/l vs. 3,16±0,98 mmol/l, p<0,01), and the mass of LP-PLA2 (296±70 ng/ml vs. 237±76 ng/ml, p<0,005) comparing to the patients with EH and CHD. In multifactorial regression analysis it was shown that only concentration of LP-PLA2 independently associated with CHD among native inhabitants of the Republic (β=0,66; p<0,001). We did not found association of LP-PLA2 with presence and prominence of carotid atherosclerosis and carotid intima-media thickness (p>0,05).Conclusion. In Kirgiz ethnic group there is association of LP-PLA2 with CHD, but not with carotid atherosclerosis.

коронарная болезнь сердцакаротидный атеросклерозЛП-ФЛА2coronary heart diseasecarotid atherosclerosisLP-PLA2ReferencesLazzini A, Lazzini S. Cardiovascular disease: an economical perspective. Curr. Pharm. Des. 2009; 15, 10:1142-56.Lazzini A, Lazzini S. Cardiovascular disease: an economical perspective. Curr. Pharm. Des. 2009; 15, 10:1142-56.Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003; 290(7): 898-904.Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003; 290(7): 898-904.MсMacphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol 2001; 1: 121-5.MсMacphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol 2001; 1: 121-5.Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med. 2005 Oct; 2(10): 529-35.Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med. 2005 Oct; 2(10): 529-35.Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A 1988; 85(8): 2805-9.Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A 1988; 85(8): 2805-9.Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010 May 1; 375(9725): 1536-44.Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010 May 1; 375(9725): 1536-44.Campo S, Sardo MA, Bitto A, et al. Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals. Clin Chem. 2004 Nov; 50(11): 2077-82.Campo S, Sardo MA, Bitto A, et al. Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals. Clin Chem. 2004 Nov; 50(11): 2077-82.Kiortsis DN, Tsouli S, Lourida ES, et al. Lack of association between carotid intimamedia thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology. 2005 Jul-Aug; 56(4): 451-8.Kiortsis DN, Tsouli S, Lourida ES, et al. Lack of association between carotid intimamedia thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology. 2005 Jul-Aug; 56(4): 451-8.Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000; 150(2): 413-9.Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000; 150(2): 413-9.Singh U, Zhong S, Xiong M, et al. Increased plasma non-esterified fatty acids and plateletactivating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice. Clin Sci (Lond) 2004; 106(4): 421-32.Singh U, Zhong S, Xiong M, et al. Increased plasma non-esterified fatty acids and plateletactivating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice. Clin Sci (Lond) 2004; 106(4): 421-32.Brilakis ES, Khera A, Saeed B, et al. Association of Lipoprotein-associated Phospholipase A2 mass and activity with coronary and aortic atherosclerosis: finding from the Dallas Heart Study. Clin Chem 2008; 54(12): 1975-81.Brilakis ES, Khera A, Saeed B, et al. Association of Lipoprotein-associated Phospholipase A2 mass and activity with coronary and aortic atherosclerosis: finding from the Dallas Heart Study. Clin Chem 2008; 54(12): 1975-81.Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, highsensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109(7): 837-42.Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, highsensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109(7): 837-42.Persson M, Hedblad B, Nelson JJ, et al.. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects Arterioscler Thromb Vasc Biol. 2007 Jun; 27(6): 1411-6.Persson M, Hedblad B, Nelson JJ, et al.. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects Arterioscler Thromb Vasc Biol. 2007 Jun; 27(6): 1411-6.Oldgren J, James SK, Siegbahn A, et al. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 2007 Mar; 28(6): 699-704.Oldgren J, James SK, Siegbahn A, et al. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 2007 Mar; 28(6): 699-704.O’Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006; 113(14): 1745–52.O’Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006; 113(14): 1745–52.Muzzio ML, Miksztowicz V, Brites F, et al. Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res. 2009; 40(1): 48-53Muzzio ML, Miksztowicz V, Brites F, et al. Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res. 2009; 40(1): 48-53Yamamoto I, Fujitsu J, Nohnen S, et al. Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2003 Mar; 59(3): 219-24.Yamamoto I, Fujitsu J, Nohnen S, et al. Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2003 Mar; 59(3): 219-24.Kardys I, Oei HH, van der Meer IM, et al. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Thromb Vasc Biol. 2006 Mar; 26(3): 631-6.Kardys I, Oei HH, van der Meer IM, et al. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Thromb Vasc Biol. 2006 Mar; 26(3): 631-6.Garg PK, McClelland RL, Jenny NS, et al. Association of lipoprotein-associated phospholipase A(2) and endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA). Vasc Med. 2011 Aug; 16(4): 247-52.Garg PK, McClelland RL, Jenny NS, et al. Association of lipoprotein-associated phospholipase A(2) and endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA). Vasc Med. 2011 Aug; 16(4): 247-52.

The authors declare that there are no conflicts of interest present.